Autoimmune Encephalitis pediatric treatment considerations
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes
|
Autoimmune Encephalitis Microchapters |
|
Differentiating Autoimmune Encephalitis from Other Conditions |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune Encephalitis On the Web |
Overview
Autoimmune encephalitis treatment in children requires pediatric neurology expertise, developmentally appropriate assessment, and individualized immunotherapy. The international pediatric treatment consensus specifically addresses N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis; its recommendations should not automatically be applied to every childhood inflammatory brain disorder.[1]
When to Start Treatment
Autoimmune encephalitis should be assessed urgently while infectious, metabolic, genetic, epileptic, and psychiatric alternatives are investigated. In a functionally impaired child meeting possible pediatric diagnostic criteria, immunotherapy may begin while antibody results are pending. Subsequent absence of antibodies and objective evidence of neuroinflammation should prompt diagnostic reassessment rather than automatic escalation.[2]
Autoimmune encephalitis treatment should follow appropriate sampling and reasonable exclusion of infection. Empirical antiviral treatment is needed when herpes simplex encephalitis remains possible; immune treatment decisions require coordination with the infectious-diseases team.[3]
Pediatric NMDAR Antibody Encephalitis
First-Line Treatment
Autoimmune encephalitis associated with NMDAR antibodies is initially treated with corticosteroids, preferably intravenous pulses. Add intravenous immunoglobulin (IVIG) or therapeutic plasma exchange in severe disease. Subsequent pulses, tapering, and treatment duration depend on response.[1]
Escalation and Maintenance
Autoimmune encephalitis associated with NMDAR antibodies may require second-line rituximab when improvement is inadequate approximately two weeks after starting two or more first-line therapies. Assess the effect of second-line treatment over weeks; refractory cases may require further specialist-directed treatment after approximately 1–3 months, generally allowing more than six weeks. Maintenance immunosuppression beyond six months is usually unnecessary except with severe, prolonged, or relapsing disease. Recovery can be slow.[1]
Other Subtypes and Antibody-Negative Disease
Autoimmune encephalitis without NMDAR antibodies requires treatment matched to the clinical syndrome, diagnostic certainty, and supporting investigations. Pediatric antibody-negative disease requires careful exclusion of mimics. Apparent improvement after corticosteroids alone does not confirm an autoimmune diagnosis.[2]
Drug and Procedural Safety
Autoimmune encephalitis regimens in children require weight- or body-surface-area-based prescribing, maximum-dose checks, and specialist protocols; adult regimens must not simply be copied. Review the following treatment-specific risks:
- Corticosteroids: Infection, hyperglycemia, hypertension, sleep disruption, and behavioral effects.
- IVIG: Infusion reactions, thrombosis, and renal complications.
- Plasma exchange: Vascular-access complications, hypotension, electrolyte disturbance, and bleeding.
- Cyclophosphamide: Marrow suppression, infection, bladder toxicity, and potential gonadal injury.[3]
Autoimmune encephalitis treatment with rituximab requires hepatitis B screening, baseline blood counts, vaccination review, and monitoring for serious infection and infusion reactions.[4]
Tumor-Directed Treatment
Autoimmune encephalitis associated with pediatric NMDAR antibodies requires early tumor investigation and timely removal when an associated tumor is identified. Repeat investigation may be needed with poor response or relapse. Negative imaging does not establish a need for empirical removal of normal ovaries.[1]
See screening for an associated neoplasm and surgery.
Supportive Care and Rehabilitation
Autoimmune encephalitis may require seizure treatment, respiratory support, nutritional assistance, and management of agitation or autonomic instability alongside immunotherapy.[3] Cognitive difficulties and fatigue can persist despite physical improvement; assess school participation and arrange neuropsychological and educational support.[5]
Evidence and Coordination of Care
Autoimmune encephalitis treatment recommendations largely reflect observational evidence and expert consensus. A 2024 single-center study associated implementation of a pediatric clinical pathway with shorter time to investigation and treatment; it does not establish a universal regimen or prove comparative drug efficacy.[6]
Related Chapters
- Pediatric considerations: presentation and diagnostic assessment.
- Medical therapy: general treatment framework.
- Interventions: procedural treatment.
- Symptomatic and supportive therapy: symptom management and rehabilitation.
References
- ↑ 1.0 1.1 1.2 1.3 Nosadini M, Thomas T, Eyre M, et al. International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2021;8(5):e1052. doi:10.1212/NXI.0000000000001052. PMID:34301820.
- ↑ 2.0 2.1 Cellucci T, Van Mater H, Graus F, et al. Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. Neurol Neuroimmunol Neuroinflamm. 2020;7(2):e663. doi:10.1212/NXI.0000000000000663. PMID:31953309.
- ↑ 3.0 3.1 3.2 Abboud H, Probasco JC, Irani S, et al. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry. 2021;92(7):757–768. doi:10.1136/jnnp-2020-325300. PMID:33649022.
- ↑ Genentech. Rituxan (rituximab): prescribing information. DailyMed, United States National Library of Medicine.
- ↑ de Bruijn MAAM, Aarsen FK, van Oosterhout MP, et al. Long-term neuropsychological outcome following pediatric anti-NMDAR encephalitis. Neurology. 2018;90(22):e1997–e2005. doi:10.1212/WNL.0000000000005605. PMID:29703768.
- ↑ Barter KM, Fuchs C, Graham TB, Pagano LM, Vater M. Anti-NMDAR Encephalitis Clinical Practice Guideline: Improving Time to Diagnosis, Treatment, and Hospital Length of Stay. Neurol Clin Pract. 2024;14(1):e200218. doi:10.1212/CPJ.0000000000200218. PMID:38173540.